| Trial ID: | L1528 |
| Source ID: | NCT00614679
|
| Associated Drug: |
Catheter Lock Solution Consisting Of N-Acetylcystein, Tigecycline And Heparin
|
| Title: |
A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End-Stage Renal Disease|Hemodialysis Catheter-associated Infection
|
| Interventions: |
DRUG: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
|
| Outcome Measures: |
Primary: Treatment success within 90 days, 90 days | Secondary: catheter salvage, 90 days
|
| Sponsor/Collaborators: |
Sponsor: University of California, San Diego
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-10
|
| Completion Date: |
2009-12
|
| Results First Posted: |
|
| Last Update Posted: |
2019-10-09
|
| Locations: |
Ben Taub General Hospital, Houston, Texas, 77030, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, 77030, United States|The Methodist Hospital, Houston, Texas, 77030, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00614679
|
